Novo Nordisk's acquisition of Catalent will negatively impact operating profit and free cash flow.

From GlobeNewswire: 2024-12-14 00:08:22

Novo Nordisk’s acquisition of Catalent, Inc. has fulfilled all regulatory closing conditions and is set to be completed in the coming days. The acquisition will have a low single-digit negative impact on operating profit growth and negatively impact free cash flow. The transaction is expected to have a mid single-digit negative impact on operating profit growth in 2025, mainly debt-financed with interest payments affecting net financial items. Novo Nordisk’s capital allocation priorities prioritize internal growth investments, dividends, and external growth opportunities. Novo Nordisk is not planning to initiate a share buyback program in 2025.



Read more at GlobeNewswire: The acquisition of Catalent by Novo